Background {#Sec1}
==========

Gingivitis, a common problem that in some can lead to periodontitis, can develop as a reaction to dental plaque \[[@CR1]\]. The occurrence of gingivitis can be limited by curtailing plaque build-up through actions including tooth brushing and the use of medicinal mouthwashes that can reach parts of the mouth that may be missed when brushing \[[@CR2], [@CR3]\].

Chlorhexidine digluconate (CHX), used in dentistry for around 40 years \[[@CR3]\], has antibacterial properties against both gram-positive and gram-negative species \[[@CR1], [@CR4]\] including those associated with periodontal disease \[[@CR5]\]. Following use of CHX-containing mouthwash, about a third of the active ingredient remains on the teeth, pellicle, oral mucosa, tongue and in salivary proteins \[[@CR3], [@CR6]\], providing sustained antibacterial properties for 8--12 h \[[@CR6]\]. These actions, especially when combined with tooth brushing, can lead to break up of existing plaque, reduction of plaque re-growth and inhibition of the development of gingivitis \[[@CR7]--[@CR10]\].

CHX mouthwashes may be recommended by dental professionals for use over a period of a few weeks or months in those for whom gingivitis is problematic \[[@CR10]\]. However, CHX is associated with significantly increased levels of staining compared to non-CHX mouthwashes \[[@CR10], [@CR11]\], which may lead to reluctance to use a CHX mouthwash as prescribed. Adding a toothpaste with good stain control qualities to this oral healthcare regimen could make the use of a CHX mouthwash more acceptable to those concerned about staining. As staining is associated with the presence of plaque \[[@CR12]\], measures to try and prevent CHX staining could include use of dentifrices with plaque-limiting ingredients. One such ingredient is sodium bicarbonate (NaHCO~3~), which works by enhancing physical removal of plaque biofilm \[[@CR13]\]. An added advantage of NaHCO~3~ is that it has very low abrasivity \[[@CR14]\], thus lowering potential damage found with some stain-limiting ingredients with high abrasivity \[[@CR15]\].

To investigate the stain control properties of NaHCO~3~, this study compared twice daily brushing with a sodium fluoride (NaF) dentifrice containing 67 % NaHCO~3~ versus a commercially available NaF silica dentifrice without NaHCO~3~ during 6 weeks use of a mouthwash containing 0.2 % CHX.

Methods {#Sec2}
=======

This 6-week, randomised, single centre (Intertek Clinical Research Services, UK), two site (Site 1: Manchester, UK; Site 2: Maldon, UK) examiner-blind, parallel-group study under the same Principal Investigator compared the stain control effect of twice daily brushing with a 67 % NaHCO~3~-containing dentifrice versus a standard dentifrice when both were used in combination with a 0.2 % CHX mouthwash. This study was reviewed by the National Research Ethics Service Committee East Midlands, Northampton. There were two protocol amendments, both for purely administrative reasons, of which the review committee was informed. This study is in ClinicalTrials.gov (NCT01962493) with results published on the GSK Clinical Study Register website \[[@CR16]\].

During screening, subjects gave their written informed consent to participate in the study in accordance with the Declaration of Helsinki \[[@CR17]\]. Demographics, medical history and concomitant medications were recorded, followed by an oral examination (which included an oral soft tissue \[OST\] examination), gross stain assessment and a gingival bleeding assessment (see below) to confirm study suitability. Subjects were 18--64 years of age, in good general and oral health (excluding gingivitis) with a minimum of 11 of 12 permanent gradable anterior teeth and, as a means to assess the presence of gingivitis, a total of at least 15 bleeding sites as measured by the Saxton & Van der Ouderra Bleeding Index (BI, a modification of the Gingival Index) \[[@CR18]\] where 0 = no bleeding after 30 s, 1 = bleeding upon probing after 30 s, 2 = immediate bleeding observed; the score was converted to bleeding (score of 1 or 2) or no bleeding (score of 0) to determine the number of bleeding sites in the mouth.

Following screening, eligible candidates were provided with a standard washout dentifrice (Control dentifrice, see below) for use at home for one timed minute twice daily, applied in a strip to cover the head of a supplied toothbrush (Aquafresh Clean Control Medium toothbrush, GSK Consumer Healthcare \[GSKCH\], Weybridge, UK, to be used throughout the study) until the baseline visit (up to 14 days after screening). At this visit subjects underwent a full OST exam and a stain assessment using the modified Lobene Stain Index (MLSI) on MacPherson sites (see description below and Fig. [1](#Fig1){ref-type="fig"}). Intra-oral digital images were taken of the relevant facial and lingual surfaces of the anterior teeth to provide a record of tooth stain before and after product use, these were not used for stain rating. A dental prophylaxis and floss was carried out on the anterior teeth used to assess the stain to clean and remove all stain to ensure they were free of all plaque and supra- and sub-gingival calculus both visually and by tactile assessment. Hence, all subjects had an MLSI score of 0 prior to study treatment use. Throughout the study the use of other oral care products including other mouthwashes, antimicrobial lozenges, chewing gums or floss (except for impacted food removal) was not allowed.Fig. 1Diagram of MacPherson tooth areas with MLSI grading sites on the two central upper incisors. G = Gingival; B = Body; M = Mesial; D = Distal

A randomisation schedule generated by the Biostatistics and Data Management Department of GSKCH stratified subjects based on site, baseline MLSI score (low Facial MLSI \<45, high Facial MLSI ≥45) and smoking status. All subjects received mint flavour, alcohol free Corsodyl® 0.2 % mouthwash containing 0.2 % CHX (GSKCH, Weybridge, UK). Subjects were allocated to either a NaHCO~3~ dentifrice: Corsodyl® Daily Gum and Toothpaste containing 67 % NaHCO~3~ and 1400 ppm fluoride as NaF (relative dentin abrasivity \[RDA\] ∼47.6) (GSKCH, Weybridge, UK) or a Control dentifrice without NaHCO~3~: Aquafresh® Fresh & Minty Toothpaste containing 1450 ppm fluoride as NaF (RDA ∼93.0) (GSKCH, Weybridge, UK). Study dentifrices were supplied in commercial packaging then over-wrapped to blind study staff and subjects to treatment assignment. CHX mouthwash was supplied in its commercial packaging.

Subjects were instructed to apply a strip of dentifrice to cover the toothbrush head and brush in their usual manner for one timed minute then thoroughly rinse their mouth with water. Five timed minutes after brushing, subjects rinsed for one timed minute with 10 mLs of 0.2 % CHX mouthwash. To ensure treatment compliance, subjects' first use of their allocated products was carried out under supervision at the site. Subjects then used their assigned product at home twice daily for 6 weeks, with use reported on a supplied diary card that was checked at all study visits. At Weeks 3 and 6 ± 2 days post baseline, subjects returned to the site and underwent a full OST examination followed by stain assessments using the MLSI index.

Objectives {#Sec3}
----------

The primary objective was to determine whether brushing with a 67 % NaHCO~3~ dentifrice produced a greater level of stain control than brushing with a non-NaHCO~3~ dentifrice following 6 weeks usage, as indicated by Overall (total facial and lingual) MLSI stain Intensity multiplied by Area (IxA) scores. Secondary objectives were to compare Overall MLSI treatment differences following 3 weeks of usage; to compare differences between treatments on stain-control levels after 3 and 6 weeks of treatment, as indicated by the individual MLSI (IxA) scores for each region (Overall Interproximal, Overall Facial, Overall Gingival and Interproximal), and to monitor oral adverse events (AEs) using OST examination.

Procedures and assessments {#Sec4}
--------------------------

### Gross stain assessment {#Sec5}

An examination to ascertain oral health and gross level of stain was performed. Subjects needed to have a sufficient level of stain at screening to be eligible. Stain levels on the facial surfaces of the six maxillary and six mandibular anterior teeth needed to be at least 'mild' (i.e. mild, moderate or severe) and present on a minimum of four teeth out of the 12 maxillary and mandibular teeth evaluated.

### MLSI using MacPherson's sites \[[@CR19], [@CR20]\] {#Sec6}

Stain was assessed on air-dried teeth by a single qualified examiner after the subject had brushed the teeth to be assessed with water for 10 s to remove any loose debris. Assessment was made of the area and intensity of dental stain on the facial surfaces of the maxillary and mandibular anterior teeth and lingual surfaces of the mandibular anterior teeth, surfaces that cosmetically are the most apparent with respect to stain accumulation. Each surface was divided into four regions (see Fig. [1](#Fig1){ref-type="fig"}).Gingival (G) = a crescent-shaped band about 2 mm wide running parallel to the gingival margin; the limit of the G region is toward the incisal edge, marked by the end of the interdental papillaBody (B) = the central area of the buccal/lingual aspect, between G and D/M sites, extending to the incisal edgeMesial (M) = the visible area of the tooth facing *toward* the central midline, ending at the interdental papilla (G site start), bordered by the B areaDistal (D) = the visible area of the tooth facing *away from* the central midline, ending at the interdental papilla (G site start), bordered by the B area

The MLSI is derived from the products of the Intensity and Area scores (IxA scores) of all regions.

### Stain intensity {#Sec7}

The intensity of stain was scored separately for each region using the following criteria:0 = No stain1 = Light stain2 = Moderate stain3 = Heavy stain

### Stain area {#Sec8}

The area of stain was scored separately for each region using the following criteria:0 = No stain1 = Stain up to 1/3 of the area affected2 = Stain between 1/3 and 2/3 of the area affected3 = Stain more than 2/3 of area affected

The MLSI (IxA) scores were calculated at the site level first and then averaged over the whole regions of interest (Overall, Overall Interproximal, Overall Facial, Overall Gingival and Interproximal), as detailed in Table [1](#Tab1){ref-type="table"}.Table 1Relevant tooth site for calculation of MLSI scoreVariableSurfacesRegionSummary (Average over)Overall MLSIMax-F, Man-F, Man-L (18)GBMD (4)18 × 4 = 72 sitesOverall Facial MLSIMax-F, Man-F (12)GBMD (4)12 × 4 = 48 sitesOverall Interproximal MLSIMax-F, Man-F, Man-L (18)MD (2)18 × 2 = 36 sitesOverall Gingival and Interproximal MLSIMax-F, Man-F, Man-L (18)GMD (3)18 × 3 = 54 sites*Max-F* maxillary-facial, *Man-F* mandibular-facial, *Man-L* mandibular-lingual, *G* gingival, *B* body, *M* mesial and *D* distal

### OST assessment {#Sec9}

The OST examination was accomplished by direct observation and palpation with retraction aids as appropriate. Any post-treatment soft tissue abnormality observed by the examiner or reported by the subject was recorded as an adverse event.

All adverse events, treatment-related or not, were also recorded.

Statistical analysis {#Sec10}
--------------------

### Sample size {#Sec11}

It was planned to screen sufficient number of subjects to randomise a maximum of 160 (80 to each treatment group), ensuring at least 70 evaluable subjects per group completed the Week 6 assessment, this being the number calculated to provide 90 % power to detect a difference between treatment groups of 0.364 in the MLSI (IxA) at Week 6, assuming a standard deviation of 0.66 \[[@CR21]\], using a two sample *t*-test with a 0.05 two-sided significance level.

The primary population for assessment of efficacy was the intent-to-treat (ITT) population, defined as those who received study treatment and had at least one post-baseline efficacy measurement. Analysis of Covariance (ANCOVA) was used to analyse the MLSI (IxA) at Weeks 3 and 6. The model included treatment, site and smoking status as factors and the relevant baseline MLSI (IxA) score as a covariate. A factor for treatment by study site interaction was included and retained in the model as it was significant at the 10 % level. Since the treatment by site interaction was significant, a post-hoc analysis by study site was carried out with factors for treatment and smoking status and baseline as a covariate. Residuals from the model showed departures from normality and a square root transformation improved the distribution and was applied to the data. Resulting means and confidence intervals (CIs) were back transformed \[[@CR22]\].

### Assessment of examiner {#Sec12}

Weighted Kappa coefficients, along with 95 % CIs, were calculated to assess the intra-examiner repeatability for MLSI (IxA) assessments at each visit. Repeatability was deemed to represent excellent replication if the kappa coefficient was greater than 0.75, fair to good replication if the value was between 0.4 and 0.75 inclusive and poor replication if the value was below 0.4.

Results {#Sec13}
=======

Baseline summary {#Sec14}
----------------

In total, 314 subjects were screened and 160 were randomised (99 at Site 1, 61 at Site 2), of whom 150 completed the study. All 160 subjects were treated so were included in the Safety population. Their mean age was 39.6 (range 18--64), they were mainly female (72.5 %), white (78.1 %) and non-smokers (77.5 %). Most subjects had a facial MLSI (IxA) score at baseline of \<45 (90.0 %) with a mean baseline BI score of 0.5, comparable for each group (Table [2](#Tab2){ref-type="table"}).Table 2Summary of the demographics and baseline characteristics for the Safety population (*n* = 160)67 % NaHCO~3~ dentifrice + mouthwash *N* = 78Control dentifrice + mouthwash *N* = 82Male n (%)22 (28.2 %)22 (26.8 %)Female n (%)56 (71.8 %)60 (73.2 %)Mean age (±SD)39.8 (11.08)39.5 (10.87)Age range19--6418--63Ethnicity n (%)White56 (71.8)69 (84.1)Black9 (11.5)5 (6.1)Asian9 (11.5)2 (2.4)Multiple4 (5.1)6 (7.3)Smoker n (%)Yes18 (23.1)18 (22.0)No60 (76.9)64 (78.0)Total facial MLSI (IxA) score n (%)Low (\<45)72 (92.3)72 (87.8)High (≥45)6 (7.7)10 (12.2)Mean Bleeding Index (±SD)0.5 (0.50)0.5 (0.50)Mean Overall MLSI (IxA) (±SD)^a^0.78 (0.710)0.74 (0.610)Site n (%)149 (62.8)50 (61.0)229 (37.2)32 (39.0)^a^From ITT population (*n* = 75, 79); *n* number, *SD* standard deviation

Of the 160 subjects, six provided no post-baseline efficacy data leading to an ITT population of 154 (95 at Site 1, 59 at Site 2). Fourteen of the 160 subjects had protocol violations leading to total exclusion and a Per Protocol (PP) population of 146 (Fig. [2](#Fig2){ref-type="fig"}). Due to similar numbers between ITT and PP populations (\<10 % difference), PP analysis was not performed. The study was carried out between 16 September 2013 and 20 November 2013.Fig. 2Trial profile. PP = Per Protocol; ITT = Intent-to-treat

Efficacy results {#Sec15}
----------------

For all comparisons, the 67 % NaHCO~3~ dentifrice had numerically lower MLSI scores than the Control dentifrice. However, there was no significant difference between treatments for the primary efficacy variable of Overall MLSI at 6 weeks (−19.9, *P* = 0.1313). The Overall Facial MLSI was significantly different at Week 6, favouring the 67 % NaHCO~3~ dentifrice (−32.2 %, *P* = 0.0404) (Table [3](#Tab3){ref-type="table"}, Fig. [3](#Fig3){ref-type="fig"}).Table 3Summary of treatment differences in MLSI regions by week (ITT population *n* = 154)RegionWeekDifference (95 % CI)^b^% Diff^b^*P*-valueOverall MLSI3−0.09 (−0.24, 0.06)−22.60.15526^a^−0.20 (−0.51, 0.10)−19.90.1313Overall Facial MLSI3−0.09 (−0.20, 0.01)−39.20.05296−0.23 (−0.49, 0.02)−32.2**0.0404**Overall Interproximal MLSI3−0.13 (−0.36, 0.09)−22.00.18736−0.28 (−0.74, 0.18)−18.40.1713Overall Gingival and Interproximal MLSI3−0.12 (−0.31, 0.07)−22.80.16146−0.23 (−0.60, 0.15)−18.20.1709^a^Primary objective; ^b^ *Diff* difference is 67 % NaHCO~3~ dentifrice minus control dentifrice. A negative difference favours the former. Results are based on back transformed data based on square root transformation; bold text indicates a statistically significant valueFig. 3Unadjusted Overall MLSI score by treatment time (± standard error). BL = Baseline; PROPHY = Prophylaxis; MW = Mouthwash; MLSI = modified Lobene Stain Index

There was a significant treatment site interaction; a post-hoc investigation of the data by site showed different treatment effects at each (Table [4](#Tab4){ref-type="table"}; Fig. [4](#Fig4){ref-type="fig"}).Table 4Summary of treatment differences by site (ITT population *n* = 154)SiteWeekDifference (95 % CI)% Diff^a^*P*-value*Overall MLSI* 13−0.26 (−0.43, −0.09)−52.1**0.0016**6−0.44 (−0.77, −0.10)−41.2**0.0072** 230.08 (−0.16, 0.31)22.60.462160.05 (−0.44, 0.54)5.50.8038*Facial overall MLSI* 13−0.19 (−0.32, −0.06)−64.8**0.0019**6−0.40 (−0.68, −0.12)−53.0**0.0032** 230.00 (−0.17, 0.17)1.20.97576−0.04 (−0.45, 0.36)−6.40.8105*Overall interproximal MLSI* 13−0.36 (−0.62, −0.10)−49.7**0.0043**6−0.61 (−1.12, −0.10)−39.2**0.0126** 230.10 (−0.25, 0.45)19.40.542160.09 (−0.65, 0.83)6.00.7888*Overall gingival and interproximal MLSI* 13−0.31 (−0.53, −0.09)−51.0**0.0029**6−0.50 (−0.91, −0.09)−39.6**0.0108** 230.08 (−0.21, 0.38)19.00.540960.09 (−0.52, 0.69)6.90.7550^a^Diff = Difference is 67 % NaHCO~3~ dentifrice minus control dentifrice. A negative difference favours 67 % NaHCO~3~ dentifrice. Results based on back transformed data based on square root transformation; bold text indicates a statistically significant value.Fig. 4Mean Overall MLSI score by treatment, study site (centre) and time (unadjusted means ± standard error). BL = Baseline; PROPHY = Prophylaxis; MW = Mouthwash; MLSI = modified Lobene Stain Index

At Site 1, for Overall MLSI (IxA) score at both 3 and 6 weeks there were significant differences of −52.1 % (*P* = 0.0016) and −41.2 % (*P* = 0.0072) in favour of the 67 % NaHCO~3~ dentifrice group. However, no such significant differences were seen at Site 2 for either week. Similarly, all secondary efficacy variables were significantly different for Site 1 and none were significantly different at Site 2.

Repeatability {#Sec16}
-------------

The repeatability analysis of the MLSI Index (based on 30 subjects) showed excellent agreement between the first and repeat assessments for both area and intensity. The weighted kappa value for MLSI-Area was 0.91 (95 % CI = 0.89, 0.93) and MLSI-Intensity was 0.92 (95 % CI = 0.90, 0.94).

Safety results {#Sec17}
--------------

Overall, 80 subjects (50.0 %) reported at least one AE, with a total of 142 AEs. All of the 31 treatment-related AEs reported by 28 subjects (17.5 %) were oral AEs (Table [5](#Tab5){ref-type="table"}). Three subjects withdrew due to AEs; two in the Control group: one due to dysgeusia and one due to glossodynia, and one subject from the 67 % NaHCO~3~ dentifrice group due to appendicitis and ruptured ovarian cyst. There were three serious AEs reported by two subjects: one had autoimmune pancreatitis, reported pre-treatment, and one had appendicitis and a ruptured ovarian cyst, reported during the study. None of these AEs were treatment related.Table 5Treatment emergent adverse events (Safety population *N* = 160)67 % NaHCO~3~ dentifrice + MW (*N* = 78)Control dentifrice + MW (*N* = 82)*n (%)nAEn (%)nAE*All AEs39 (50.0)7041 (50.0)72Oral AEs21 (26.9)2433 (40.2)43Treatment Related AEs11 (14.1)1217 (20.7)19Treatment-related oral AEs Dysgeusia1 (1.3)17 (8.5)7 Paraesthesia oral3 (3.8)34 (4.9)4 Glossodynia2 (2.6)23 (3.7)4 Tongue discolouration4 (5.1)400 Ageusia1 (1.3)12 (2.4)2 Sensitivity of teeth1 (1.3)11 (1.2)1 Hypoaesthesia oral001 (1.2)1*MW* mouthwash; *n (%)* number (percent) of subjects with at least one AE; *nAE* number of adverse events

Discussion {#Sec18}
==========

Studies have shown that CHX-containing mouthwash is an effective way to reduce gingivitis \[[@CR7], [@CR9]\]. However, people may be reluctant to use CHX mouthwash as prescribed as it can cause tooth staining \[[@CR10], [@CR11]\]. As staining levels are associated with plaque occurrence, one way to help counteract stain is by minimising plaque build-up through, for instance, the use of NaHCO~3~-containing dentifrice, which can help physically remove plaque biofilm \[[@CR13], [@CR23]\].

In this study, stain accumulation at 6 weeks was higher than had been seen at baseline, suggesting that indeed CHX use led to increased levels of staining. While the 67 % NaHCO~3~ dentifrice group showed a numerically lower level of stain compared to the Control dentifrice group, the difference in Overall MLSI (IxA) (a combined measure of maxillary and mandibular facial and mandibular lingual staining) was not significant at either 3 or 6 weeks. The Overall Facial MLSI was statistically significantly different at Week 6, favouring the 67 % NaHCO~3~ dentifrice. This was the only measure to exclude the lingual surface, which is of interest as the facial surfaces are known to be easier to clean than the lingual ones.

To examine factors that may have led to a finding of non-significance overall, the study results were broken down by site in a post-hoc analysis. For Site 1 there were significant differences favouring the 67 % NaHCO~3~ dentifrice at both weeks and for all areas including overall MLSI; this was not shown for Site 2. Examiner variations were ruled out as the same examiner was used at both sites and the same hygienist carried out the majority of the prophylaxes at both sites. The randomisation process and storage conditions of the study supplies were also checked and no issues found. There were differences in the clinical suite lighting: Site 1 used a 5000 K bulb, Site 2 a 3550 K bulb, but this was not thought to affect assessments as there were similarities in baseline data between study sites. Another factor could be that there was a difference in the consumption of stain-causing drinks by site; however, the fact that baseline staining and Week 6 control dentifrice values were very similar may not support this postulate.

A factor of interest was that there was a difference in water hardness with Site 1 (Manchester) classified as 'very soft' (average 9.3 milligrams/litre calcium \[mg/l Ca\]) \[[@CR24]\] and Site 2 (Maldon) as 'hard to very hard' (range 98--120 mg/l Ca) \[[@CR25]\]. It was queried as to whether or not this could have affected the results. An in vitro study showing that staining intensity with a combination of tea and CHX mouthwash was greater with hard water \[[@CR26]\] would mean that this current study should have had higher Week 6 staining levels with the Control dentifrice at Site 2, which was not the case; hence, any differences could be due to potential interaction factors between water hardness and the effectiveness of NaHCO~3~ as opposed to being due to interactions with the CHX mouthwash.

Conclusion {#Sec19}
==========

In summary, no significant difference in stain levels was found between a dentifrice containing NaHCO~3~ and one without this ingredient when using a mouthwash containing 0.2 % CHX. Differences were seen in facial surface staining after 6 weeks, suggesting effectiveness of NaHCO~3~ dentifrice on more accessible surfaces. As differences were seen at different sites, further investigation may be warranted.
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